
    
      Patients are randomized to 1 of 2 open-label treatment groups. Group 1 receives ddI EC plus
      d4T plus NLF for 48 weeks. Group 2 receives ddI plus d4T plus NLF for 48 weeks. Both forms of
      ddI are administered orally once daily. Antiviral activity is determined by the magnitude and
      the duration of reduction of plasma HIV RNA from baseline through Week 24.
    
  